Imbio RV/LV Software vs IM007
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A specializes in automated analysis of CTPA scans to measure ventricular diameters, aiding in risk stratification for acute pulmonary conditions. In contrast, Tool B is a remote monitoring platform that aggregates and analyzes data from cardiac implantable electronic devices to streamline workflows and manage alerts for chronic cardiac patients. While both leverage AI in cardiology and are FDA-cleared, they address distinct clinical needs and utilize different data sources.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Imbio RV/LV Software is an AI-powered tool that automatically measures right and left ventricular diameters from CTPA scans to aid in risk stratification for pulmonary conditions like pulmonary embolism. In contrast, Implicity's IM007 is an AI-powered, cloud-based platform for remote cardiac monitoring, aggregating data from all cardiac implantable electronic devices (CIEDs) to streamline workflows and improve patient outcomes in cardiology and heart failure management.
Imbio RV/LV Software processes volumetric CTPA acquisitions in DICOM format as input. Implicity's IM007 aggregates data from various cardiac implantable electronic devices (CIEDs) from manufacturers such as Abbott, Biotronik, Boston Scientific, Medtronic, and MicroPort.
Imbio RV/LV Software is designed for integration with standard reading environments like PACS. Implicity's IM007 offers EHR integration capabilities through a bidirectional API and integration framework, and it is a cloud-based SaaS solution.
Imbio RV/LV Software utilizes an artificial intelligence algorithm for automated ventricle identification and measurement from CTPA scans. Implicity's IM007 features AI-driven alert management to reduce false positives (e.g., 79% for ILR ECG Analyzer, 85% for AF alerts), an FDA-cleared AI for ICM ECG data analysis (ILR ECG Analyzer), and an FDA-cleared predictive AI for heart failure hospitalization risk (SignalHF).